About Anumana AI
Anumana is an AI-driven health technology company developing ECG algorithms enabling early diagnosis and intervention for cardiovascular diseases.
Mission & Story
Mission
We develop and commercialize evidence-based AI solutions designed to enable earlier detection and improve patient care across the entire cardiac care continuum.
Clinical Focus
Medical conditions and clinical areas addressed by Anumana AI.
Who It Serves
Milestones & Awards
Recent Milestones
FDA clearance for ECG-AI Cardiac Amyloidosis algorithm (April 2026 - first and only). Expanding into perioperative cardiac care with generative AI imaging technologies. Multiple peer-reviewed publications in 2024-2026 including Nature Medicine, JACC, European Heart Journal.
Key Partnerships
Social & Media
Follow on
Latest Updates
The Real Test for AI Diagnostics Isn’t Performance — It’s Clinical Adoption
Supporting Predictive Analytics to Improve Clinical Decision Making and Patient Outcomes
Anumana Makes Educated Inferences in Heart Failure
Bridging ECG Signals and EHR data through Contrastive Learning
Anumana Appoints Kevin Ballinger and Jean-Luc Butel to Board of Directors
Company Details
- Founded
- 2021
- Headquarters
- Cambridge, MA, USA
- Employees
- 175
- Stage
- series c
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Similar Companies in this Market
View all 64 →
AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Aisap
11-50 employees
AISAP provides FDA-cleared AI-powered diagnostic algorithms embedded in an operating system for point-of-care ultrasound (POCUS) devices. The platform enables rapid, expert-level cardiac imaging interpretation at the bedside, helping physicians detect structural heart disease early and make faster clinical decisions across hospitals, clinics, and screening programs.
AliveCor
AliveCor develops FDA-cleared, AI-powered ECG devices and software platforms for cardiac monitoring. The company offers portable ECG solutions ranging from consumer personal devices to clinical-grade 12-lead systems, serving patients, healthcare providers, biopharma companies, and health systems with remote and connected cardiac care.
Artrya
11-50 employees
Artrya develops AI-powered solutions for rapid assessment of chest pain patients in emergency and primary care settings. The company's technology analyzes coronary computed tomography angiography (CCTA) to detect arterial plaque and stratify patient risk within minutes.
Bay Labs
Bay Labs is a health AI company focused on cardiology and cardiovascular health. The company's website is currently under construction with limited public information available.
BunkerHill Health
Bunkerhill Health provides Carebricks, an AI-powered platform that enables health systems to design, deploy, and operationalize AI agents across clinical and operational workflows. The platform reasons across patient data and automates actions within existing EHR systems.
Caption Health, Inc
Caption Health develops AI-powered ultrasound guidance technology that enables healthcare providers to capture high-quality cardiac ultrasound images, expanding access to diagnostic imaging beyond traditional specialists.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.